Receives USFDA Final Approval for Dapagliflozin Tablets - Alembic Pharmaceuticals Ltd

Code BSE: 533573 NSE:

Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Dapagliflozin Tablets, 5 mg and 10 mg. Therefore, with this approval, Alembic is eligible for 180 days of shared generic drug exclusivity.